The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 ...

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

Lynch syndrome demands proactive health management, including regular screenings like colonoscopies and endoscopies, to ...

Testicular cancer is rare but highly curable, especially with early detection; treatment varies by stage, and follow-up care ...

Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology ...

It isn’t easy having cancer. But like gardening in a harsh climate, survival and growth come from strategies, adaptation, and ...

I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...